XJPX4575
Market cap93mUSD
Jan 14, Last price
895.00JPY
1D
-0.67%
1Q
-4.28%
Jan 2017
47.20%
IPO
-74.79%
Name
CanBas Co Ltd
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
10.34%
Revenues
0k
Net income
-1.21b
L-2.82%
CFO
-1.28b
L-8.49%
Profile
CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 2,158,000 | 1,636,964 | 1,454,438 | ||
Unusual Expense (Income) | |||||
NOPBT | (2,158,000) | (1,636,964) | (1,454,438) | ||
NOPBT Margin | |||||
Operating Taxes | 1,000 | 1,250 | 1,250 | ||
Tax Rate | |||||
NOPAT | (2,159,000) | (1,638,214) | (1,455,688) | ||
Net income | (1,209,000) -2.82% | (1,244,108) 45.41% | (855,577) 61.12% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 1,538,279 | 2,254,531 | 650,013 | ||
BB yield | -15.90% | -12.23% | -10.34% | ||
| Debt | |||||
Debt current | |||||
Long-term debt | 367,344 | ||||
Deferred revenue | |||||
Other long-term liabilities | 1,000 | ||||
Net debt | (2,012,200) | (1,635,795) | (402,431) | ||
| Cash flow | |||||
Cash from operating activities | (1,280,192) | (1,398,936) | (719,814) | ||
CAPEX | |||||
Cash from investing activities | 182 | ||||
Cash from financing activities | 1,538,270 | 2,272,621 | 282,751 | ||
FCF | (2,236,537) | (1,934,237) | (1,454,242) | ||
| Balance | |||||
Cash | 1,888,200 | 1,617,795 | 737,775 | ||
Long term investments | 124,000 | 18,000 | 32,000 | ||
Excess cash | 2,012,200 | 1,635,795 | 769,775 | ||
Stockholders' equity | (5,231,217) | (4,831,943) | (5,024,064) | ||
Invested Capital | 7,572,084 | 6,719,470 | 5,611,389 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 17,814 | 14,983 | 9,687 | ||
Price | 543.00 -55.85% | 1,230.00 89.52% | 649.00 61.85% | ||
Market cap | 9,673,163 -47.51% | 18,429,351 193.13% | 6,287,173 106.73% | ||
EV | 7,660,963 | 16,793,556 | 5,884,742 | ||
EBITDA | (2,158,000) | (1,636,964) | (1,454,438) | ||
EV/EBITDA | |||||
Interest | 1,169 | 5,680 | |||
Interest/NOPBT | |||||